FDA Accepts Sarepta’s sNDAs for Duchenne Treatments AMONDYS 45 and VYONDYS 53 — Sarepta Therapeutics, Inc.

Event summary

FDA accepted sNDAs for AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen), seeking conversion from accelerated to traditional approval.
PDUFA target action date set for February 28, 2027.
Applications supported by ESSENCE study data and real-world evidence showing muscle function preservation and slowed disease progression.
Over 1,800 patients treated worldwide with Sarepta’s exon-skipping therapies.

The big picture

Sarepta’s sNDA filings mark a critical step in solidifying the long-term viability of its exon-skipping therapies for Duchenne muscular dystrophy. The FDA’s acceptance reflects growing regulatory adaptability for rare disease treatments, but the outcome will hinge on the agency’s evaluation of real-world evidence and confirmatory trial data. Success could further entrench Sarepta’s leadership in precision genetic medicine for rare diseases.

What we're watching

Regulatory Outcome: Whether the FDA will convert accelerated approvals to traditional approvals for AMONDYS 45 and VYONDYS 53 by the PDUFA date.
Clinical Efficacy: How the ESSENCE study data and real-world evidence will influence long-term patient outcomes and market adoption.
Competitive Positioning: The pace at which Sarepta can expand its exon-skipping portfolio to address more DMD mutations.